Linked Life Data

17220605

Source:http://linkedlifedata.com/resource/pubmed/id/17220605

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-1-15
pubmed:abstractText
Cancer is caused by genetic abnormalities: activation of oncogenes and functional inactivation of tumor-suppressor genes. Direct correction of these abnormalities should be the essential treatment for cancer; however, we have not developed any techniques to effectively fix the genome to date. Molecular biological analyses have demonstrated the cancer function of abnormal gene products, activated signal transduction pathways, and cancer-specific cell surface antigens. Molecular target drugs have been designed to suppress these molecules, important for maintaining cancer status, at stages of mRNA and protein. Some targets contributing to cancer progression are even within host cells such as angiogenic factor receptors. Differing from conventional chemotherapeutic agents screened and developed with cytotoxicity to tumor cells, molecular target drugs show higher specificity for cancer and sometimes simply stabilize the tumor. The effect of such drugs depends on the expression and functional importance of the target in cancer, and prediction of the effect using molecular techniques such as DNA microarray may be necessary for appropriate use.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1349-7235
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
87-9
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
1. Molecular target drug discovery.
pubmed:affiliation
Department of Internal Medicine, Division of Hematology, National Defense Medical College, Saitama. fkimura@ndmc.ac.jp
pubmed:publicationType
Journal Article, Review